期刊文献+

辨证治疗化疗相关性腹泻26例 被引量:8

Syndrome Differentiation Based Treatment for Chemotherapy Induced Diarrhea: A Report of 26 Cases
暂未订购
导出
摘要 目的观察化疗相关性腹泻(chemotherapy induced diarrhea,CID)中医辨证论治的疗效。方法将38例CID患者分为治疗组和对照组,治疗组26例采用中医辨证治疗,对照组12例采用黄连素、思密达或易蒙停治疗。结果治疗组脾虚型、湿热型、脾肾阳虚型、肝郁脾虚型分别为14、10、1、1例,有效例数分别为11、7、1、1例;治疗组和对照组总有效率分别为76.9%、50.0%,两组总有效率比较,差异无统计学意义(P>0.05)。结论 CID的常见证型为脾虚型、脾肾阳虚型,辨证治疗有较好的疗效。 Objective To study the therapeutic effects of syndrome differentiation based treatment,a therapy in traditional Chinese medicine(TCM),in treating chemotherapy induced diarrhea(CID).Methods A total of 26 patients were allocated into treatment group and control group.Twenty-six patients in the treatment group were treated with TCM treatment based on syndrome differentiation,and another 12 patients in the control group were treated with berberine and Smecta,or Loperamide.Results Of 26 CID patients in the treatment group,14,10,1,and 1 were diagnosed as spleen deficiency type,damp-heat type,spleen-kidney yang deficiency type,and liver depression and spleen deficiency type,respectively;and the effective cases were 11,7,1,and 1 in above-mentioned syndrome types,respectively.The total effective rate was 76.9% and 50% in the treatment group and the control group,respectively;there was no significant difference in total effective rate between the two groups.Conclusion The common syndrome types in CID patients are spleen deficiency and spleen-kidney yang deficiency,and syndrome differentiation based treatment has better effects on CID.
出处 《安徽中医学院学报》 CAS 2011年第3期32-34,共3页 Journal of Anhui Traditional Chinese Medical College
关键词 化疗相关性腹泻 中医药疗法 辨证论治 chemotherapy induced diarrhea traditional Chinese medicine therapy syndrome differentiation based treatment
  • 相关文献

参考文献7

二级参考文献14

  • 1杨光,李发胜,刘辉,咸丰.党参多糖对小鼠免疫功能的影响[J].中药药理与临床,2005,21(4):39-39. 被引量:84
  • 2贾立群 李学 万冬桂.中药预防喜树碱衍生物引起腹泻不良反应的临床观察[J].中华中西医临床杂志,2004,4(6):701-703.
  • 3黄文东.实用中医内科学[M].上海:上海科学技术出版社,1986..
  • 4Limonti A,C elibter A,Pavese I,et al.New approaches to prevent intestinal toxicity of irnotecan-based regimens[J].Cancer Treat Rev,2004,30(6):555-562.
  • 5Trifan OC,Durham WF.Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11[J].Cancer Research,2002,15,62(20):5778-84.
  • 6Akinobu Kurita,Kado S.Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats[J].Cancer Chemother Pharmacol,2000,46(3):211-20.
  • 7Chiu Ct.Intestinal mucosal lesion in low flow states[J].Arch Surg,1970,101:478-485.
  • 8名倉宏 長橋雅人 名倉洋子 他.粘膜免疫と生体防御[J].Biotherapy,2004,18(1):19-25.
  • 9Limonti A,Gelibter A,Pavese I et al.New approaches to prevent intestinal toxicity of irnotecan-based regimens[J].Cancer Treat Rev,2004;30(6):555-562.
  • 10Trifan O C,Durham W F,Salazar V S et al.Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11[J].Cancer Research,2002; 62(20):5778-5784.

共引文献54

同被引文献157

引证文献8

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部